China News Service, May 19 (Reporter Chen Jing) The reporter was informed on the 19th that a related clinical trial conducted by Zhong Nanshan's team, an academician of the Chinese Academy of Engineering, found that for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), hydrogen and oxygen therapy is superior to Oxygen therapy is safe and well tolerated.
This means that inhalation of hydrogen/oxygen mixture may be used as an alternative emergency treatment for acute exacerbations of chronic obstructive pulmonary disease.
Related papers were published in the British "Respiratory Research" ("Respiratory Research") magazine.
The paper means that hydrogen medicine is moving towards a high-level clinical research stage.
Researchers told reporters that although hydrogen medicine has a 14-year history of discovery and more than 100 research papers on human trials, there was a lack of high-quality clinical research evidence in the past.
The so-called high quality refers to multi-center double-blind controlled clinical trials.
Chronic obstructive pulmonary disease (CPOD), or chronic obstructive pulmonary disease, is a lung disease characterized by obstructive ventilation of the small bronchi.
Severe breathing difficulties and acute exacerbations are the main causes of mortality from the disease.
At present, the application of bronchodilator drugs, non-invasive ventilation and oxygen therapy are important ways to improve symptoms and slow down the progression of the disease.
Previous studies have proved that hydrogen molecules have the characteristics of anti-inflammatory, anti-oxidation, and rapid diffusion.
Related research jointly carried out by the State Key Laboratory of Respiratory Diseases, the National Respiratory Disease Clinical Research Center and many other units compares the effects of mixed hydrogen and oxygen inhalation with oxygen inhalation to determine whether hydrogen can play a role.
According to reports, the trial intervention method is based on a 1:1 ratio. The researchers randomly assigned the subjects to the trial group and the control group. The trial group received the adjuvant treatment of a hydrogen-oxygen atomizer; the control group received the assistance of a medical oxygen generator. Treatment: Patients in the two groups inhaled for 6-8 hours a day, and the treatment cycle was 7 days.
The trial recruited patients at 10 centers, and they scored at least 6 points for dyspnea, cough, and sputum.
The results of the study showed that the scores related to dyspnea, cough and sputum in the hydrogen/oxygen group changed more than those in the oxygen group, indicating that inhalation of hydrogen/oxygen mixture can significantly improve the symptoms of acute COPD attacks (including dyspnea, cough and sputum).
There have been no reports of clinical trials using hydrogen/oxygen mixtures to treat acute exacerbations of COPD, which provides strong evidence for exploring the mechanism of action and clinical applications of hydrogen-oxygen mixtures.
The paper pointed out that hydrogen and oxygen therapy may be an alternative to long-term family oxygen therapy in the future.
(Finish)